Abstract 566P
Background
The incidence of lower gastrointestinal tract (GI) cancers among adolescents and young adults (AYAs) is rising. A cancer diagnosis and treatment(s) can lead to long-term morbidity and disrupt physical, cognitive, and psychosocial development, which can result in a reduced health-related quality of life (HRQOL) in this young population. The aim of this study was to describe the long-term survivorship outcomes of AYA with lower GI cancer.
Methods
The Netherlands Cancer Registry identified AYA cancer survivors (aged 18-39 years at initial cancer diagnosis, 5-20 years past diagnosis). They were invited to participate in a population-based, cross-sectional questionnaire study (SURVAYA). Survivorship issues (EORTC QLQ-SURV111) and HRQOL (EORTC QLQ-C30) were assessed. For this secondary analysis, we used data of all participating AYA colorectal and anal cancer patients.
Results
82 SURVAYA participants were selected (43% colon, 47% rectal and 8% anal cancer; 59% male sex; mean age 34 years at study participation; 11.3 years after diagnosis). Primary treatment consisted of surgery (18%); surgery and chemotherapy (23%); surgery and radiotherapy (10%); radiotherapy and chemotherapy (10%); surgery, radiotherapy and chemotherapy (39%); 35% of patients had a stoma. AYA cancer survivors reported to some extent issues related to body image (41%), sexual intimacy (41%), fertility (49%), social isolation (43%), uncertainty about future (71%), reduced career opportunities (55%), reduced income (41%), and getting a mortgage/insurance (49%). Compared to the normative population, AYA cancer survivors experienced higher levels of fatigue (31.9 vs. 19.4), pain (15.4 vs. 11.4), insomnia (22.4 vs 17.3) and diarrhea (16.2 vs. 5.5); and reported lower physical (89.7 vs. 94.8), role (81.1 vs. 91.7), emotional (77.7 vs. 85.4), cognitive (80.0 vs. 92.0) and social functioning (85.3 vs. 93.6). Overall HRQOL was lower for AYAs compared to the norm (72.1 vs. 75.9; all p<0.05).
Conclusions
A substantial proportion of AYA lower GI cancer survivors reports long-term psychosocial and physical survivorship issues. Access to tailored age-specific healthcare resources is needed to maximize their HRQOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute.
Funding
Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10